Journal of Internal Medicine 1993: **234**: 631–636

Author Index

Åberg H, *see* Danielsson & Åberg, 411
Abildgaard U, *see* Heldal *et al.*, 71
Adlercreutz H, *see* Hautanen & Adlercreutz, 461
Akama H, *see* Tanaka *et al.*, 257
Alanen A, *see* Koivunen-Niemelä *et al.*, 401
Alberti KGMM, *see* Shmueli *et al.*, 397
d'Allens H, *see* Bousser *et al.*, 211
Aloe Spiriti MA, *see* Fiermonte G, 599
Amir G, *see* Leibowitz G, 625
Amland PF, *see* Samdal *et al.*, 489
Andersen, LB, Haraldsdóttir J. Tracking of cardiovascular disease risk factors including maximal oxygen uptake and physical activity from late teenage to adulthood. An 8-year follow-up study, 309
Andersson, C, *see* Bjersing L, 339
Arbiser JL, Goldstein AM, Gordon D. Thrombocytopenia following administration of phenytoin, dexamethasone and cimetidine: a case report and a potential mechanism, 91
Areskog, M, *see* Nyman *et al.*, 293
Areskog N-H, *see* Nyman *et al.*, 293
Arnqvist HJ, Halban PA, Mathiesen UL, Zahnd G, Von Schenck H. Hypoglycaemia caused by atypical insulin antibodies in a patient with benign monoclonal gammopathy (Case report), 421
Ascari E, *see* Ucci *et al.*, 165
Ashizawa N, Yamashita S, Usa T, Hayashi I, Kapuku GK, Kuo Y, Tokunaga Y, Urano T, Yano K. Lack of evidence of exon 13 mutations in the beta cardiac myosin heavy chain gene with familial hypertrophic cardiomyopathy in Japan (Letter to the Editor), 341
Asplund K, *see* Lindahl *et al.*, 263
Atkins PC, *see* Tanus *et al.*, 525

Backeljauw P, *see* Underwood *et al.*, 571
Baggi V, *see* Pezzarossa *et al.*, 325
Barbieri MA, *see* Kajiwara *et al.*, 181
Barradas MA, Mikhailidis DP. Accelerated coronary artery disease after heart transplantation: the role of enhanced platelet aggregation and thrombosis (Letter to the Editor), 433
Belenkov Yu, *see* Samsonov *et al.*, 139
Benediktsdóttir B, *see* Gíslason *et al.*, 31
Benker G, *see* Olbricht & Benker, 137
Bergbrant A, Hansson L, Jern S. Correspondence between screening and intra-arterial blood pressures in young men with borderline hypertension, 201
Berger M, *see* Sawicki *et al.*, 407
Bergqvist D, *see* Sterner *et al.*, 281
Bergström K, *see* Karlberg *et al.*, 513
Berntorp E, *see* Holm *et al.*, 303
Bharathi KC, *see* Muthane *et al.*, 611
Bianchi Porro G, Pace F. Rationale and efficacy of medical therapy for gastro-oesophageal reflux disease (Review), 387
Birkeland KI, *see* Samdal *et al.*, 489
Bjersing L, Andersson C, Lithner F. Easy detection of mutations in acute intermittent porphyria and hepatocellular carcinoma on paraffin-embedded tissue (Letter to the Editor), 339
Björkholm M, *see* Engervall *et al.*, 231; Gruber *et al.*, 223
Björkholm M. Intravenous immunoglobulin treatment in cytopenic haematological disorders (Review), 119
Bjorntorp P. Hyperandrogenicity in women—a prediabetic condition? (Review), 579
Black CM. The aetiopathogenesis of systemic sclerosis (Review), 3
Black CM. Scleroderma—clinical aspects (Minireview), 115
Blum WF, *see* Wüster C, 249
Boeri G, *see* Patrassi *et al.*, 619
Boissonnat P, *see* de Lorgeril *et al.*, 434
Bolognesi R, *see* Pezzarossa *et al.*, 325
Bonora E, *see* Zavaroni *et al.*, 25
Boscaro M, *see* Fallo F, 595
Bousser MG, d'Allens H, Richard A. Efficacy of subcutaneous sumatriptan in the acute treatment of early-morning migraine: a placebo-controlled trial and the Early-Morning-Migraine Sumatriptan Study Group, 211
Brandstätter G, *see* Wurzer *et al.*, 521
Breathnach A, *see* Buggy *et al.*, 453
Briewa L, *see* Rashiq *et al.*, 507
Brzezińska A, *see* Słowińska-Srzednicka *et al.*, 447
Buggy D, Breathnach A, Keogh B, Cooke T, Feely J. Lipoprotein(a) and treatment of chronic renal disease, 453
Burman P, *see* Karlsson *et al.*, 379

Carlsson R, *see* Holm *et al.*, 303
Carrascosa M, *see* Castrillon *et al.*, 102
Castrillon JLP, Mendez MA, Carrascosa M, Valle R. Dr Castrillon's reply [to Jansen] (Correspondence), 102
Chan P, Lee CP, Yang CY, Hung JS. Complete membranous obstruction of the inferior vena cava: clinical characteristics of Chinese patients, 501
Chen J, *see* Karlberg *et al.*, 513
Cheng TO. Angiotensin-converting enzyme inhibition and physical training in heart failure (Letter to the Editor), 340
Cheng TO. The sauna and the heart (Correspondence), 101
Chotkowska E, *see* Słowińska-Srzednicka *et al.*, 447
Christiansen JS, *see* Hansen *et al.*, 175
Chua TP, Fry IDR, Frankel RJ, Lim R. Serum cholesterol concentration before and after steptokinase in acute myocardial infarction, 603
Ciurana AJ, *see* le Quellec *et al.*, 329
Cooke T, *see* Buggy *et al.*, 453
Cooperative Group for the Study and Treatment of Multiple Myeloma, *see* Ucci *et al.*, 165
Crepaldi G, *see* Zambon *et al.*, 217
Curb JD, *see* Laws *et al.*, 471
Czirjak L, Nagy Z, Szegedi G. Survival analysis of 118 patients with systemic sclerosis (Short communication), 335

Dahlöf B, *see* Johannesson *et al.*, 317
Dahlöf B, Hansson L. The influence of antihypertensive therapy on the structural arteriolar changes in essential hypertension: different effects of enalapril and hydrochlorothiazide, 271
Dalekos GN, *see* Tsianos *et al.*, 607

Dall'aglio E, *see* Zavaroni *et al.*, 25
Danielsson B, Åberg H. Hyperlipidaemia—management and views amongst physicians in general practice, in occupational health care and in internal medicine, 411
Delsignore R, *see* Zavaroni *et al.*, 25
Denig P, Haaijer-Ruskamp FM, Wesseling H, Versluis A. Drug expectations and drug choices of hospital physicians, 155
Didjurgeit U, *see* Sawicki *et al.*, 407
Drucker M, *see* Leibovici *et al.*, 83
Dureau G, *see* de Lorgeril *et al.*, 434

Early-Morning-Migraine Sumatriptan Study Group, *see* Bousser *et al.*, 211
Efendic S, Östenson C-G. Hormonal responses and future treatment of non-insulin-dependent diabetes mellitus (NIDDM) (Frontiers in medicine), 127
Eggstein M, *see* Knisel *et al.*, 479
Ekbom T, *see* Johannesson *et al.*, 317
Eliakim R, *see* Leibowitz *et al.*, 625
Elis A, Lishner M, Lang R, Savin H, Ravid M. Haemorrhagic bullae induced by oral anticoagulants, 615
Elisaf M, *see* Tsianos *et al.*, 607
Engervall P, Björkholm B, Petrini B, Heurlin N, Henriques B, Kallenius G. Disseminated *Mycobacterium malmoense* infection in a patient with chronic granulocytic leukaemia (Case report), 231
Erhardt L, *see* Holm *et al.*, 303
Erikssen J, *see* Erikssen *et al.*, 493
Erikssen G, Thaulow E, Sandvik L, Stormorken H, Erikssen J. Haematocrit: a predictor of cardiovascular mortality? 493
Estrov Z, *see* Wetzler *et al.*, 417
Eykyn SJ, *see* Leibovici *et al.*, 83
de Faire U, *see* Lemne *et al.*, 9
Fallo F, Paoletta A, Tona F, Boscaro M, Sonino N. Response of hypertension to conventional antihypertensive treatment and/or steroidogenesis inhibitors in Cushing's syndrome, 595
Fantuzzi M, *see* Zavaroni *et al.*, 25
Farahat K, Hainaut P, Jamar F, Haot J, Lambert M. Lymphocytic gastritis: an unusual cause of hypoproteinaemia (Case report), 95
Feely J, *see* Buggy *et al.*, 453
Fiermonte G, Aloe Spiriti MA, Latagliata R, Petti MC, Giacomini P. Polycythaemia vera and cerebral blood flow: a preliminary study with transcranial Doppler, 599
Frankel RJ, *see* Chua *et al.*, 603
Froesch ER, Hussaim M. IGFs: function and clinical importance (Minisymposium). 5. Therapeutic potential of rhIGF-I in diabetes and conditions of insulin resistance, 561
Froesch ER. IGFs: function and clinical importance (Minisymposium). 1. Editorial introduction, 533
Fry IDR, *see* Chua *et al.*, 603
Fujiyama, K, *see* Ikeda *et al.*, 61

Gamstedt A, Holm-Glad J, Ohlson C-G, Sundström M. Hand abnormalities are strongly associated with the duration of diabetes mellitus, 189
Giacomini P, *see* Fiermonte *et al.*, 599
Giancarlo T, *see* Rashiq *et al.*, 507
Gilli P, *see* Zambon *et al.*, 217
Girolami A, *see* Patrassi *et al.*, 619
Gíslason T, Reynisdóttir H, Kristbjarnarson H, Benediktsdóttir B. Sleep habits and sleep disturbances among the elderly—an epidemiological survey, 31
Goldstein AM, *see* Arbiser *et al.*, 91
Gordon D, *see* Arbiser *et al.*, 91
Gransden WR, *see* Leibovici *et al.*, 83
Grove JS, *see* Laws *et al.*, 471
Gruber A, Lundberg L-G, Björkholm M. Reactivation of chronic hepatitis withdrawal of immunosuppressive therapy (Case report), 223
Gutterman JU, *see* Wetzler *et al.*, 417

Haaijer-Ruskamp FM, *see* Denig *et al.*, 155
de Haan AFJ, *see* Stalenhoef *et al.*, 77
Hacibertasoglu A, *see* Ozyilkan *et al.*, 436
Hagerman I, *see* Karlberg *et al.*, 513
Hainaut P, *see* Farahat *et al.*, 95
Halban PA, *see* Arnqvist *et al.*, 421
Hallas J, Hansen N-CG. Individual utilization of anti-asthma medication by young adults: a prescription database analysis, 65
Hallmans G, *see* Lindahl *et al.*, 263
Hanaki K, *see* Ohzeki *et al.*, 227
Hansen KW, Pedersen MM, Christiansen JS, Mogensen CE. Diurnal blood pressure variations in normoalbuminuric type 1 diabetic patients, 175
Hansen N-CG, *see* Hallas & Hansen, 65
Hansson L, *see* Bergbrant *et al.*, 201; Dahlöf & Hansson, 271; Johannesson *et al.*, 317
Haot J, *see* Farabat *et al.*, 95
Haraldsdóttir J, *see* Andersen *et al.*, 309
Harnocourt K, *see* Wurzer *et al.*, 521
Hautanen A, Adlercreutz H. Altered adrenocorticotropin and cortisol secretion in abdominal obesity: implications for the insulin resistance syndrome, 461
Hayashi I, *see* Ashizawa *et al.*, 341
Heitmann BL, *see* Rudniki *et al.*, 195
Heldal M, Seem E, Sandset PM, Abildgaard U. Deep vein thrombosis: a 7-year follow-up study, 71
Helve E, Tuominen JA, Koivisto VA. Captopril does not acutely enhance insulin sensitivity, 41
Henriques B, *see* Engervall *et al.*, 231
Heurlin N, *see* Engervall *et al.*, 231
Hjermann I, *see* Lund Håheim *et al.*, 17
Holland WW, Mosbech J. International quality control of national scientific standards (Editorial), 1
Holm J, Berntorp E, Carlsson R, Erhardt L. Low-dose warfarin decreases coagulability without affecting prothrombin complex activity, 303
Holm-Glad J, *see* Gamstedt *et al.*, 189
Holme I, *see* Lund Håheim *et al.*, 17
Hoshino T, *see* Ikeda *et al.*, 61
Hultberg B, *see* Sterner *et al.*, 281
Hulthén L, *see* Sterner *et al.*, 281
Hung JS, *see* Chan *et al.*, 501
Hussain M, *see* Froesch *et al.*, 561

Ichikawa Y, *see* Tanaka *et al.*, 257
Ikeda T, Terasawa H, Ishimura M, Ochi H, Ohtani I, Fujiyama K, Hoshino T, Tanaka Y, Mashiba H. Correlation between blood pressure and plasma insulin in acromegaly, 61
Ikeda Y, *see* Tanaka *et al.*, 257
Isaksson A, *see* Sterner *et al.*, 281
Ishimura M, *see* Ikeda *et al.*, 61

Jamar F, *see* Farahat *et al.*, 95

Jansen TLThA. Aetiologic factors in SIADH (Correspondence), 102
Jantunen E, Soppi E, Neittaanmäki H, Lahtinen R. Essential cryofibrinogenaemia, leukocytoclastic vasculitis and chronic purpura (Case report), 331
Jensen R, *see* Pedersen *et al.*, 457
Jern S, *see* Bergbrant *et al.*, 201
Jeske W, *see* Słowińska-Srzednicka *et al.*, 447
Johannesson M, Dahlöf B, Lindholm LH, Ekbom T, Hansson L, Odén A, Scherstén B, Wester P-O, Jönsson B. The cost-effectiveness of treating hypertension in elderly people—an analysis of the Swedish Trial in Old Patients with Hypertension (STOP Hyertension), 317
Johansson AG, Lindh E, Ljunghall S. IGFs: function and clinical importance (Minisymposium). 4. Growth hormone, insulin-like growth factor I, and bone: a clinical review, 553
Jönsson B, *see* Johannesson *et al.*, 317
Jørgensen M, *see* Pedersen *et al.*, 457
Jørgensen T, *see* Rudnicki *et al.*, 195

Kajiwara JK, Zucoloto S, Manço ARX, Muccillos G, Barbieri MA. Accuracy of clinical diagnoses in a teaching hospital: a review of 997 autopsies, 181
Kallenius G, *see* Engervall *et al.*, 231
Kämpe O, *see* Karlsson *et al.*, 379
Kapuku GK, *see* Ashizawa *et al.*, 341
Karlberg K-E, Chen J, Hagerman I, Bergström K, Wallin R, Saldeen T, Sylvén C. Streptokinase, but not tissue plasminogen activator, attenuates platelet aggregation in patients with acute myocardial infarction, 513
Karlsson FA. Autoimmune endocrinopathies (Minisymposium). 1. Editorial introduction, 345
Karlsson FA, Kämpe O, Winqvist O, Burman P. Autoimmune endocrinopathies (Minisymposium). 5. Autoimmune disease of the adrenal cortex, pituitary, parathyroid glands and gastric mucosa, 379
Kastelein JJP, *see* Stalenhoef *et al.*, 77
Kayhan B, *see* Ozyilkan E, 436
Kemp GJ, *see* Thompson *et al.*, 149
Keogh B, *see* Buggy *et al.*, 453
Khatib R, *see* Rashiq *et al.*, 507
Kleinert R, *see* Wurzer *et al.*, 521
Knisel W, di Niculo A, Pfohl M, Müller H, Risler T, Eggstein M, Seifried E. Different effects of two methods of low-density lipoprotein apheresis on the coagulation and fibrinolytic systems, 479
Kockum I, *see* Lernmark *et al.*, 361
Kohno Y, *see* Ohzeki *et al.*, 227
Koivisto VA, *see* Helve *et al.*, 41
Koivunen-Niemelä T, Alanen A, Viikari J. Sonography of the Achilles tendon in hypercholesterolaemia, 401
Konsiberger H, *see* Leibovici *et al.*, 83
Kortmann B, *see* Stalenhoef *et al.*, 77
Kristbjarnarson H, *see* Gíslason *et al.*, 31
Kroon AA, *see* Stalenhoef *et al.*, 77
Krusemo UB, *see* Larsson *et al.*, 585
Kullnig P, *see* Wurzer *et al.*, 521
Kurzrock R, *see* Wetzler *et al.*, 417

Lagerlof H, Nilsson CG. Pathophysiological mechanisms operating in restenosis following coronary angioplasty (Letter to the Editor), 435
Lahtinen R, *see* Jantunen *et al.*, 331
Lambert M, *see* Farahat *et al.*, 95
Lang R, *see* Elis *et al.*, 615
Lansberg PJ, *see* Stalenhoef *et al.*, 77
Largerstrand L, Rössner S. Effects of weight loss on pulmonary function in obese men with obstructive sleep apnoea syndrome, 245
Larsson K, Ljunghall S, Krusemo UB, Naessen T, Lindh E, Persson I. The risk of hip fractures in patients with primary hyperparathyroidism: a population-based cohort study with a follow-up of 19 years, 585
Latagliata R, *see* Firemonte *et al.*, 599
Laws A, Marcus EB, Grove JS, Curb JD. Lipids and lipoproteins as risk factors for coronary heart disease in men with abnormal glucose tolerance: the Honolulu Heart Program, 471
Lee CP, *see* Chan *et al.*, 501
Leibovici L, Gransden WR, Eykyn SJ, Konsiberger H, Drucker M, Pitlik SD, Phillips I. Clinical index to predict bacteraemia caused by staphylococci, 83
Leibowitz G, Amir G, Losses IS, Eliakim R. Autoimmune polyglandular failure associated with malabsorption and gastric carcinoid tumour (Case report), 625
Lemne C, Volk-Jovinge S, Nilsson J, Vesterqvist O, de Faire U. Plasma growth factor activity and cardiac wall thickness, 9
Lerche A, *see* Pedersen *et al.*, 457
Leren P, *see* Lund Håheim *et al.*, 17
Lernmark Å, Möller C, Kockum I, Sanjeevi C. Autoimmune endocrinopathies (Minisymposium). 3. Islet cell autoimmunity, 361
Levinson AI, *see* Tanus *et al.*, 525
Lim R, *see* Chua *et al.*, 603
Lindahl B, Asplund K, Hallmans G. High serum insulin, insulin resistance and their associations with cardiovascular risk factors. The Northern Sweden MONICA population study, 263
Lindgärde F, *see* Mattiasson *et al.*, 45
Lindgren A, Ölsson R. Liver damage from low-dose oral contraceptives, 287
Lindh E, *see* Johansson *et al.*, 553; Larsson *et al.*, 585
Lindholm LH, *see* Johannesson *et al.*, 317
Lishner M, *see* Elis *et al.*, 615
Lithner F, *see* Bjersing *et al.*, 339
Ljunghall S, *see* Johansson *et al.*, 553; Larsson *et al.*, 585
de Lorgeril M, Boissonnat P, Dureau G, Renaud S. Dr de Lorgeril's reply (Letter to the Editor), 434
Losses IS, *see* Leibowitz *et al.*, 625
Lund Haaheim L, Holme I, Hjermann I, Leren P. The predictability of risk factors with respect to incidence and mortality of myocardial infarction total mortality. A 12-year follow-up of the Oslo Study, Norway, 17
Lundberg L-G, *see* Gruber *et al.*, 223
Luoni R, *see* Ucci *et al.*, 165
Luurila OJ. Mitral prolapse and sauna bathing (Correspondence), 101

MacKie RM. Sun and skin damage (Editorial), 111
Mamatha P, *see* Muthane *et al.*, 611
Manca C, *see* Pezzarossa *et al.*, 325
Manço ARX, *see* Kajiwara *et al.*, 181
Manhern P, *see* Sterner *et al.*, 281
Manzato E, *see* Zambon *et al.*, 217
Marcus EB, *see* Laws *et al.*, 471
Mareev V, *see* Samsonov *et al.*, 139

Markowitz A, *see* Wetzler *et al.*, 417
Masenko V, *see* Samsonov *et al.*, 139
Mashiba H, *see* Ikeda *et al.*, 61
Mathiesen UL, *see* Arnqvist *et al.*, 421
Mattiasson I, Lindgärde F. The effect of psychosocial stress and risk factors for ischaemic heart disease on the plasma fibrinogen concentration, 45
Mazza S, *see* Zavaroni *et al.*, 25
McLachlan SM, Rapoport B. Autoimmune endocrinopathies (Minisymposium). 2. Recombinant thyroid autoantigens: the keys to the pathogenesis of autoimmune thryoid disease, 347
Mendez MA, *see* Castrillon *et al.*, 102
Mikhailidis DP, *see* Barradas *et al.*, 433
Mogensen CE, *see* Hansen *et al.*, 175
Möller C, *see* Lernmark *et al.*, 361
Moncayo HE, *see* Moncayo & Moncayo, 371
Moncayo R, Moncayo HE. Autoimmune endocrinopathies (Minisymposium). 4. The association of autoantibodies directed against ovarian antigens in human disease: a clinical review, 371
Mooney M, *see* Rashiq *et al.*, 507
Mosbech J, *see* Holland & Mosbech, 1
Muccillo G, *see* Kajiwara *et al.*, 181
Muhlhauser I, *see* Sawicki *et al.*, 407
Müller H, *see* Knisel *et al.*, 479
Muthane UB, Vengamma B, Bharathi KC, Mamatha P. Porphyric neuropathy: prevention of progression using haemearginate (Case report), 611

Naessen T, *see* Larsson *et al.*, 585
Nagy Z, *see* Czirjak *et al.*, 335
Nassonov E, *see* Samsonov *et al.*, 139
Naumov V, *see* Samsonov *et al.*, 139
Neittaanmäki H, *see* Jantunen *et al.*, 331
di Nicuolo A, *see* Knisel *et al.*, 479
Nielsen H. Recombinant human granulocute colony-stimulating factor (rhG-CSF; filgrastim) treatment of clozapine-induced agranulocytosis (Case report), 529
Nilsson CG, *see* Lagerlof *et al.*, 435
Nilsson J, *see* Lemne *et al.*, 9
Nyman I, Areskog M, Areskog N-H, Swahn E, Wallenti NL and the RISC Study Group. Very early risk stratification by electrocardiogram at rest in men with suspected unstable coronary heart disease, 293

Ochi H, *see* Ikeda *et al.*, 61
Oden A, *see* Johannesson *et al.*, 317
Ogihara Y, *see* Ohzeki *et al.*, 227
Ohlson C-G, *see* Gamstedt *et al.*, 189
Öhrvall M, Tengblad S, Vessby B. Lower tocopherol serum levels in subjects with abdominal adiposity, 53
Ohtani I, *see* Ikeda *et al.*, 61
Ohzeki T, Tamura A, Hanaki K, Urashima H, Okuda H, Ogihara Y, Shiraki K, Utsunomiya Y, Yazaki Y. Long QT syndrome with insulin-dependent diabetes mellitus: contiguous gene syndrome on chromosome 11p (Case report), 227
Oku Y, *see* Ashizawa *et al.*, 341
Okuda H, *see* Ohzeki *et al.*, 227
Olbricht T, Benker G. Glucocorticoid-induced osteoporosis: pathogenesis, prevention and treatment, with special regard to the rheumatic diseases (Review), 237
Olsson R, *see* Lindgren *et al.*, 287
Oshima H, *see* Tanaka *et al.*, 257
Östenseon C-G, *see* Efendic & Östenson, 127
Ozyilkan E, Tatar G, Hacibertasoglu A, Kayhan B. Analysis of T-helper and T-suppressor lymphocyte subsets in patients with chronic hepatitis C virus infection, 436

Pace F, *see* Bianchi Porro *et al.*, 387
Paoletta A, *see* Fallo *et al.*, 595
Parker DR, Shaboury AH. Central hypothryoidism presenting with pericardial and pleural effusions (Case report), 429
Passeri M, *see* Zavaroni *et al.*, 25
Patrassi GM, Sartori MT, Piermarocchi S, Viero M, Boeri G, Girolami A. Unusual thrombotic-like retinopathy (Coats'disease) associated with congenital plasminogen deficiency type I (Case report), 619
Pedersen LM, Lerche A, Jørgensen M, Urhammer S, Steenberg P, Jensen R. Follow-up study of patients with clinically suspected deep venous thrombosis and a normal venogram, 457
Pedersen MM, *see* Hansen *et al.*, 175
Persson I, *see* Larsson *et al.*, 585
Petrini B, *see* Engervall *et al.*, 231
Petti MC, *see* Fiermonte *et al.*, 599
Pezzarossa A, Baggi V, Manca C, Bolognesi R. Non-paroxysmal arterioventricular junctional tachycardia during postprandial hypoglycaemia in an obese non-diabetic patient (Case report), 325
Pfohl M, *see* Knisel *et al.*, 479
Phillips I, *see* Leibovici *et al.*, 83
Piermatocchi S, *see* Patrassi *et al.*, 619
Pitlik SD, *see* Leibovici *et al.*, 83

le Quellec A, Sotto A, Ciurana AJ. Spontaneous resolution of acquired factor X deficiency in amyloidosis (Case report), 32.

Radda GK, *see* Thompson *et al.*, 149
Rajagopalan B, *see* Thompson *et al.*, 149
Ranke MB, *see* Wüster *et al.*, 249
Rapoport B, *see* McLachlan & Rapoport, 347
Rashiq S, Briewa L, Mooney M, Giancarlo T, Khatib R, Wilson FM. Distinguishing acyclovir neurotoxicity from encephalomyelitis, 507
Ravid M, *see* Elis *et al.*, 615
Reaven GM, *see* Zavaroni *et al.*, 25
Record CO, *see* Schmueli *et al.*, 397
Renaud S, *see* de Lorgeril *et al.*, 434
Reynisdóttir H, *see* Gíslason *et al.*, 31
Riccardi A, *see* Ucci *et al.*, 165
Richard A, *see* Bousser *et al.*, 211
Riis P. Fort Knox and the open scientific landscape (Editorial), 235
RISC Study Group, *see* Nyman *et al.*, 293
Risler T, *see* Knisel *et al.*, 479
Ronquist G, *see* Waldenstrom *et al.*, 432
Rössner S, *see* Largertrand & Rossner, 245
Rudnicki M, Thode J, Jørgensen T, Heitmenn BL, Sørensen OH. Effects of age, sex, season and diet on serum ionized calcium, parathyroid hormone and vitamin D in a random population, 195

Sadowski Z, *see* Słowińska-Srzednicka *et al.*, 447
Saldeen T, *see* Karlberg *et al.*, 513
Samdal F, Amland PF, Sandsmark M, Birkeland KI. Diabetic lipohypertophy treated with suction-assisted lipectomy, 489

Samsonov M, Nassonov E, Masenko V, Naumov V, Mareev V, Belenkov Yu. Anaphylatoxins in dilated cardiomyopathy, 139
Sandset PM, *see* Heldal *et al.*, 71
Sandsmark M, *see* Samdal *et al.*, 489
Sandvik L, *see* Erikssen *et al.*, 493
Sanjeevi C, *see* Lernmark *et al.*, 361
Sartori MT, *see* Patrassi *et al.*, 619
Savin H, *see* Ellis *et al.*, 615
Sawicki PT, Didjurgeit U, Mühlhauser I, Berger, M. Behaviour therapy versus doctor's anti-smoking advice in diabetic patients, 407
Schersten B, *see* Johannesson *et al.*, 317
Schlemilch S, *see* Wüster *et al.*, 249
Schmid C. IGFs: function and clinical importance (Minisymposium). 2. The regulation of osteoblast function by hormones and cytokines with special reference to insulin-like growth factors and their binding proteins, 535
Schmueli E, Alberti KGMM, Record CO, Diacylglycerol/protein kinase C signalling: a mechanism for insulin resistance? (Hypothesis), 397
Seem E, *see* Heldal *et al.*, 71
Seifried E, *see* Knisel *et al.*, 479
Shaboury AH, *see* Parker & Shaboury, 429
Shiraki K, *see* Ohzeki *et al.*, 227
Siamopoulos KC, *see* Tsianos *et al.*, 607
Słowińska-Srzednicka J, Zgliczyński S, Chotkowka E, Srzednicki M, Stopińska-Gluszak U, Jeske W, Brzezińska A, Zgliczyński W, Sadowski Z. Effects of transdermal 17β-oestradiol combined with oral progestogen on lipids and lipoproteins in hypercholesterolaemic postmenopausal women, 447
Sonino N, *see* Fallo F, 595
Soppi E, *see* Jantunen *et al.*, 331
Sørensen OH, *see* Rudnicki *et al.*, 195
Sotto A, *see* le Quellec *et al.*, 329
Srzednicki M, *see* Słowińska-Srzednicka *et al.*, 447
Stabellini N, *see* Zambon *et al.*, 217
Stalenhoef AFH, Lansberg PJ, Kroon AA, Kortmann B, de Haan AFJ, Stuyt PMJ, Kastelein JJP. Treatment of primary hypercholesterolaemia. Short-term efficacy and safety of increasing doses of simvastatin and prevastatin: a double-blind comparative study, 77
Steenberg P, *see* Pedersen *et al.*, 457
Sterner G, Weibull H, Hultberg B, Bergqvist D, Hulthén L, Isaksson A, Manhern P. Determination of urinary *N*-acetyl-beta-glucosaminidase in patients with hypertension and renal artery stenosis, 281
Stopińska-Gluszak U, *see* Słowińska-Srzednicka *et al.*, 447
Stormorken H, *see* Erikssen *et al.*, 493
Stuyt PMJ, *see* Stalenhoef *et al.*, 77
Sundström M, *see* Gamstedt *et al.*, 189
Swahn E, *see* Nyman *et al.*, 293
Sylven C, *see* Karlberg *et al.*, 513
Sylven C. Syndrome X (Letter to the Editor), 431
Szegedi G, *see* Czirják *et al.*, 335
Talpaz M, *see* Wetzler *et al.*, 417
Tamura A, *see* Ohzeki *et al.*, 227
Tanaka H, Akama H, Tominaga N, Oshima H, Ichikawa Y, Ikeda Y. Progressive renal failure in patients with lupus nephritis, 257
Tanaka Y, *see* Ikeda *et al.*, 61
Tanus T, Levinson AI, Atkins PC, Zweiman B. Polyautoimmune syndrome in common variable immunodeficiency (Case report), 525
Tarroni G, *see* Zambon *et al.*, 217
Tatar G, *see* Ozyilkan *et al.*, 436
Taylor DJ, *see* Thompson *et al.*, 149
Teisberg P. Genetics of non-insulin-dependent diabetes mellitus (NIDDM) (Editorial), 439
Telatar H, *see* Ozyilkan *et al.*, 436
Tengblad S, *see* Ohrvall *et al.*, 53
Terasawa H, *see* Ikeda *et al.*, 61
Thaulow E, *see* Erikssen *et al.*, 493
Thode J, *see* Rudnicki *et al.*, 195
Thompson CH, Kemp GJ, Taylor DJ, Radda GK, Rajagopalan B. No evidence of mitochondrial abnormality in skeletal muscle of patients with iron-deficient anaemia, 149
Tokunaga Y, *see* Ashizawa *et al.*, 341
Tominaga N, *see* Tanaka *et al.*, 257
Tona F, *see* Fallo *et al.*, 595
Tsianos EV, Dalekos GN, Elisaf M, Zervou E, Siamopoulos KC. High frequency of antibodies to Hantaan virus and hepatitis C virus in chronic haemodialysis patients. Coincidence or crossreaction? 607
Tuominen JA, *see* Helve *et al.*, 41
Tyan ML. Effect of promethazine on lumbar vertebral bone mass in postmenopausal women, 143

Ucci G, Riccardi A, Luoni R, Ascari E. (for the Cooperative Group for the Study and Treatment of Multiple Myeloma). Presenting features of monoclonal gammopathies: an analysis of 684 newly diagnosed cases, 165
Underwood LE, Backeljauw P. IGFs: function and clinical importance (Minisymposium). 6. Therapy with recombinant human insulin-like growth factor I in children with insensitivity to growth hormone and in catabolic conditions, 571
Urano T, *see* Ashizawa *et al.*, 341
Urashima H, *see* Ohzeki *et al.*, 227
Urhammer S, *see* Pedersen *et al.*, 457
Usa T, *see* Ashizawa *et al.*, 341
Utsunomiya Y, *see* Ohzeki *et al.*, 227

Valle R, *see* Castrillon *et al.*, 102
Vengamma B, *see* Muthane *et al.*, 611
Versluis A, *see* Denig *et al.*, 155
Vessby B, *see* Ohrvall *et al.*, 53
Vesterqvist O, *see* Lemne *et al.*, 9
Viero M, *see* Patrassi *et al.*, 619
Viikari J, *see* Koivunen-Niemelä *et al.*, 401
Volk-Jovinge S, *see* Lemne *et al.*, 9
Von Schenck H, *see* Arnqvist *et al.*, 421

Waldenstrom A, Ronquist G. Drs Waldenstrom's and Ronquist's reply (Letter to the Editor), 432
Wallentin L, *see* Nyman *et al.*, 293
Wallin R, *see* Karlberg *et al.*, 513
Weibull H, *see* Sterner *et al.*, 281
Wen Y-M. Hepatitis B virus precore and core gene mutations in chronic hepatitis B and hepatocellular carcinoma patients (Review), 441
Wesseling H, *see* Denig *et al.*, 155
Wester P-O, *see* Johannesson *et al.*, 317
Wetzler M, Estrov Z, Talpaz M, Markowitz A, Gutterman JU, Kurzrock R. Granulocyte–macrophage colony-stimulating factor as a cause of paraneoplastic leukaemoid reaction in advanced transitional cell carcinoma (Case report), 417
Wilson FM, *see* Rashiq *et al.*, 507

Winqvist O, *see* Karlsson *et al.*, 379
Wurzer H, Brandstätter G, Harnocourt K, Kullnig P, Kleinert R. Paraneoplastic polymyositis associated with a renal carcinoma (Case report), 521
Wüster C, Blum WF, Schlemilch S, Ranke MB, Ziegler R. Decreased serum levels of insulin-like growth factors and IGF binding protein 3 in osteoporosis, 249

Yamashita S, *see* Ashizawa *et al.*, 341
Yang CY, *see* Chan *et al.*, 501
Yano K, *see* Ashizawa *et al.*, 341
Yazaki Y, *see* Ohzeki *et al.*, 227

Zahnd G, *see* Arnqvist *et al.*, 421
Zambon A, *see* Zambon *et al.*, 217
Zambon S, Zambon A, Stabellini N, Tarroni G, Gilli P, Crepaldi G, Manzato E. Lipoprotein abnormalities in hypertriglyceridaemic patients on long-term haemodialysis, 217
Zapf J. IGFs: function and clinical importance (Minisymposium). 3. Role of insulin-like growth factor (IGF) II and IGF binding proteins in extrapancreatic tumour hypoglycaemia, 543
Zavaroni I, Mazza S, Fantuzzi M, Dall'aglio E, Bonora E, Delsignore R, Paseri M, Reaven GM. Changes in insulin and lipid metabolism in males with asymptomatic hyperuricaemia, 25
Zervou E, *see* Tsianos *et al.*, 607
Zgliczyński S, *see* Słowińska-Srzednicka *et al.*, 447
Ziegler R, *see* Wüster *et al.*, 249
Zucoloto S, *see* Kajiwara *et al.*, 181
Zweiman B, *see* Tanus *et al.*, 525

Journal of Internal Medicine 1993; **234**: 637–641

Subject Index

ACE inhibitors
  effects on arteriolar changes in essential hypertension 271
  and insulin sensitivity in IDDM 41
Achilles tendon
  in familial hypercholesterolaemia 401
Acromegaly
  hyperinsulinaemia and blood pressure 61
Acyclovir
  neurotoxicity, compared with encephalomyelitis 507
Adiposity, abdominal *see* Obesity
Adrenocorticotrophin
  abdominal adiposity and insulin resistance syndrome 461
Agranulocytosis
  clozapine-induced 529
Albumin
  and regulation of lipoprotein(a) 453
Ambulatory blood pressure
  diurnal variations in IDDM 175
Amyloidosis
  factor X deficiency 329
Anaemia
  iron deficiency, mitochondrial study 149
Anaphylotoxins
  in dilated cardiomyopathy 139
Anticoagulants
  inducing haemorrhagic bullae 615
  see also Streptokinase; Warfarin
Antihypertensive therapy
  cost-effectiveness 317
  Cushing's syndrome 595
  STOP analysis 317
Antimitochondrial antibodies
  in common variable immunodeficiency 525
Antioxidants
  tocopherol, concentrations and CHD 53
Apolipoprotein B
  changes in primary hypercholesterolaemia 77
Asthma
  drug utilization 65
Autoimmune polyglandular failure
  carcinoid tumour 625
Autopsy diagnosis
  accuracy 181

Bacteraemia, due to *Staphylococcus aureus*
  clinical index for prediction 83
Behaviour therapy
  cigarette smoking in diabetic patients 407
Beta agonists
  cost-effectiveness 317
  drug utilization in asthma 65
Blood pressure
  ambulatory, variations in IDDM 175
  enalapril effects 271
  hydrochlorothiazide effects 271
  hyperinsulinaemia in acromegaly 61
  mortality in myocardial infarction 17
  screening, correlation with later measurement 201
Bone density
  insulin-like growth factors and IGF binding protein 249
Bone marrow granuloma
  Mycobacterium malmoense infection 231
Bone marrow plasma cells
  in multiple myeloma 165
Bone mineral content
  increase, in postmenopausal women 143
Budd–Chiari syndrome
  complete membranous obstruction of vena cava 501
Bullae
  anticoagulant-induced 615

Calcium status
  age, sex, season and diet effects 195
  promethazine treatment in postmenopausal women 143
Captopril
  and insulin sensitivity in IDDM 41
Carcinoid tumour
  autoimmune polyglandular failure 625
Cardiac arrhythmia (NPJT)
  hypoglycaemia in 317
Cardiovascular disease
  cardiac hypertrophy, growth factor activity and hypertension 9
  insulin resistance 263
  lipoprotein abnormalities in hypertriglyceridaemic patients 217
  mortality prediction by haematocrit 493
  physical exercise 309
  and psychosocial stress 45
Carpal tunnel syndrome
  in diabetes mellitus 189
Central hypothyroidism
  effusions 429
Cerebral blood flow
  polycythaemia rubra vera 599
Choice behaviour *see* Decision-making process
Cholecalciferols
  age, sex, season and diet effects 195
Cholesterol, LDL
  treatment of primary hypercholesterolaemia 77
Cholesterol, serum
  incidence and mortality in myocardial infarction 17
  lipoprotein abnormalities in hypertriglyceridaemic patients 217
  streptokinase therapy in myocardial infarction 603
  subjects with NIDDM or abnormal glucose tolerance 471
  see also Familial hypercholesterolaemia
Chromosome 11p
  HLA-DR4-dependent diabetes mellitus 227
Chronic granulocytic leukaemia
  Mycobacterium malmoense infection 231
Chronic obstructive pulmonary disease
  sleep complaints, elderly people 31
Chronic renal failure
  lipoprotein(a) treatment 453
  in lupus nephritis, GFR 257

Cigarette smoking
diabetic patients, choice behaviour 407
mortality in myocardial infarction 17
Cimetidine
and drug-induced thrombocytopenia 91
Clinical diagnosis
and autopsy diagnosis 181
Clinical index
prediction of bacteraemia due to *Staphylococcus aureus* 83
Clozapine-induced agranulocytosis
filgastrim (rhG-CSF) treatment 529
Coagulase-negative staphylococcus
prediction of bacteraemia in high-risk groups 83
Coagulation system
in CHD, warfarin therapy 303
LDL apheresis effects 479
Coats' disease
congenital plasminogen deficiency 619
Common variable immunodeficiency
polyautoimmune syndrome 525
Coronary heart disease
hyperuricaemia with hyperinsulinaemia 25
hypoglycaemia and NPJT 317
mortality prediction by haematocrit 493
risk stratification, early, by ECG 293
tocopherol concentrations 53
warfarin therapy 303
Corticosteroids
drug utilization in asthma 65
effects in lupus nephritis 257
Cortisol
abdominal adiposity and insulin resistance syndrome 461
effects on psychosocial stress 45
Creatinine enzymes
myocardial infarction, ECG risk stratification 293
Cryofibrinogenaemia
leukocytoclastic vasculitis 331
Cushing's syndrome
hypertension response 595

Decision-making process
drug prescribing 155
Deep vein insufficiency
follow-up of DVT 71
Deep vein thrombosis
follow-up study 71, 453
Dexamethasone
and drug-induced thrombocytopenia 91
Dextran sulfate
LDL apheresis 479
Diabetes mellitus
ACE inhibitors and insulin sensitivity 41
cigarette smoking, behaviour therapy 407
diurnal BP variations 175
hand abnormalities 189
insulin-induced lipohypertrophy 489
long QT syndrome 227
NIDDM, risk factors for CHD 471
Diacylglycerol (DAG)
and insulin resistance 397
Dilated cardiomyopathy
anaphylotoxins 139
Diuretics
effects on arteriolar changes in essential hypertension 271
Doppler, transcranial
cerebral blood flow in polycythaemia rubra vera 599
Drug abuse
prediction of bacteraemia due to *Staphylococcus aureus* 83
Drug prescribing
decision-making process 155
Dupuytren's contracture
in diabetes mellitus 189
Dyslipidaemia
hyperuricaemia with hyperinsulinaemia 25

Elderly people
cost-effectiveness of antihypertensive therapy 317
sleep complaints 31
Electrocardiogram
very early risk stratification in CHD 293
Enalapril
arteriolar changes in essential hypertension 271
Encephalomyelitis
compared with acyclovir neurotoxicity 507
Epoxide hydrolase
and drug-induced thrombocytopenia 91

Factor VII
coagulation activity, and warfarin therapy 303
Factor X
deficiency in amyloidosis 329
Familial hypercholesterolaemia
tendon xanthomas 401
views among physicians in various settings 411
see also Cholesterol, serum
Fibrin split product
streptokinase-attenuated platelet aggregation 513
Fibrinogen
effects on psychosocial stress 45
Fibrinolytic system
Coats' disease, in congenital plasminogen deficiency 619
LDL apheresis effects 479
Flexor synovitis
in diabetes mellitus 189

G-CSF (recomb. human)
filgastrim (rhG-CSF) treatment for clozapine-induced agranulocytosis 529
Gastric carcinoid tumour
autoimmune polyglandular failure 625
Gastritis
protein-losing gastroenteropathy 95
General practitioners
views and management of hyperlipidaemia 411
Gestagens
liver damage 287
Glomerular filtration rate
renal failure in lupus nephritis 257
Glucocorticoids
and osteoporosis 237
Glucose metabolism
ACE inhibitors and insulin sensitivity in IDDM 41
Glucose tolerance test
abnormal, Honolulu Heart Program 471
blood pressure in acromegaly 61
hypoglycaemia in benign monoclonal gammopathy 421
hypoglycaemia and NPJT 317

GM-CSF
paraneoplastic leukaemoid reaction in TCC 417
Growth factor activity
hypertension 9
Growth hormone
insulin-like growth factors and IGF binding protein as parameters of secretion 249

Haematocrit
cardiovascular mortality prediction 493
in polycythaemia rubra vera 599
Haeme-arginate
in porphyric neuropathy 611
Haemodialysis patients
hepatitis C, and Hantaan virus antibodies 607
prediction of bacteraemia due to *Staphylococcus aureus* 83
Haemoglobin
polycythaemia rubra vera 599
Haemorrhagic bullae
induced by anticoagulants 615
Haemorrhagic fever with renal syndrome
haemodialysis patients 607
Hantaan virus antibodies
in chronic haemodialysis patients 607
Hepatitis C antibodies
in chronic haemodialysis patients 607
Hepatitis C, chronic
reactivation on withdrawal of immunosuppressive therapy 223
Hip fracture, risk
and osteoporosis 585
HLA
HLA-DR4-dependent diabetes mellitus, chromosome 11p 227
HMG-CoA reductase inhibitors
primary hypercholesterolaemia, treatment efficacy 77
Honolulu Heart Program
lipoproteins as risk factors for CHD 471
Hydrochlorothiazide
arteriolar changes in essential hypertension 271
Hypercholesterolaemia
postmenopause, oestradiol effects 453
primary, treatment efficacy 77
Hyperinsulinaemia
blood pressure in acromegaly 61
and coronary heart disease 25
MONICA study 263
Hyperlipidaemia
views among physicians in various settings 411
Hyperparathyroidism, primary
and osteoporotic hip fracture risk 585
Hypertension
Cushing's syndrome response 595
growth factor activity 9
hyperuricaemia with hyperinsulinaemia 25
sleep complaints, elderly people 31
STOP analysis 317
Hypertension, borderline
arterial blood pressure 201
Hypertension, essential
effects of therapy on arteriolar changes 271
U-NAG levels 281
Hyperuricaemia
CHD with hyperinsulinaemia 25

Hypoglycaemia
insulin autoantibodies 421
and NPJT 317
Hypoproteinaemia
in lymphocytic gastritis 95
Hypothyroidism
pericardial and pleural effusions 429

IL-3
and paraneoplastic leukaemoid reaction 417
Immunoadsorption
LDL apheresis 479
Immunodeficiency, common variable
polyautoimmune syndrome 525
Immunoglobulin G
monoclonal gammopathies 421
Immunosuppressive therapy
reactivation chronic hepatitis C 223
Inferior vena cava
complete membranous obstruction 501
Insulin autoantibodies
causing hypoglycaemia 421
Insulin resistance
CHD with dyslipidaemia 25
and diacylglycerol (DAG) 397
and protein kinase C 397
risk factor for cardiovascular disease 263
Insulin resistance syndrome
abdominal adiposity 461
Insulin-induced lipohypertrophy (insulin tumour)
diabetes mellitus 489
Insulin-like growth factors
IGF binding protein 249
osteoporosis 249
Insulinoma
insulin autoantibodies 421
Internists
views and management of hyperlipidaemia 411
Iron deficiency anaemia
skeletal muscle study 149
Ischaemic heart disease *see* Coronary heart disease

Joint mobility
in diabetes mellitus 189

Kappa-coefficient
autopsy diagnosis 181
Ketoconazole
hypertension response 595
Kidney failure *see* Renal failure

Left ventricular hypertrophy
growth factor activity and hypertension 9
Leucocyte count
effects on psychosocial stress 45
Leukocytoclastic vasculitis
cryofibrinogenaemia 331
Lifestyle
risk factor for CVD 309
Lipoproteins
abnormalities in hypertriglyceridaemic patients 217
Honolulu Heart Program 471
LDL, apheresis 479

lipoprotein(a), treatment of chronic renal disease 453
risk factors for CHD, adiposity 53
Liver damage
oral contraceptives 287
Long QT syndrome
in IDDM 227
Lupus nephritis
serum creatinine and GFR 257
Lymphocytic gastritis
hypoproteinaemia 95

Magnetic resonance spectroscopy
skeletal muscle in iron deficiency anaemia 149
Malabsorption
gastric carcinoid tumour 625
Migraine
sumatriptan treatment 211
MONICA population study
risk factor for cardiovascular disease 263
Monoclonal gammopathies
benign, atypical insulin bodies 421
in multiple myeloma 165
Multiple myeloma
monoclonal gammopathies 165
Mycobacterium malmoense infection
in chronic granulocytic leukaemia 231
Myocardial infarction
ECG risk stratification 293
risk factors and incidence 17
streptokinase therapy, cholesterol serum before/after 603
streptokinase-attenuated platelet aggregation 513

Non-paroxsysmal arterioventricular junctional tachycardia
and hypoglycaemia and NPJT 317

Obesity
obstructive sleep apnoea syndrome 245
Obesity, abdominal
insulin resistance syndrome 461
risk factor for CHD 53
Obstructive sleep apnoea syndrome
effect of weight loss 245
Occupational health care
views and management of hyperlipidaemia 411
Oestrogen
liver damage 287
17β-oestradiol, postmenopausal hypercholesterolaemia 453
postmenopausal, and promethazine treatment 143
Oral contraceptives
liver damage 287
Osteopenia
promethazine treatment in postmenopausal women 143
Osteoporosis
glucocorticoid-induced 237
and hip fracture risk 585
insulin-like growth factors 249

Palmar flexor synovitis
in diabetes mellitus 189
Paraneoplastic leukaemoid reaction
transitional cell carcinoma 417
Paraneoplastic polymyositis
with renal carcinoma 521
Parathyroid hormone
age, sex, season and diet effects 195
Percutaneous renal angioplasty
U-NAG levels before/after surgery 257
Pericardial effusions
and central hypothyroidism 429
Phenytoin
and drug-induced thrombocytopenia 91
Phosphate metabolism
and calcium status 195
Physical exercise
risk factor for CVD 309
Plasminogen deficiency
Coats' disease 619
Platelet aggregation
inhibition, streptokinase 513
Platelet count
effects on psychosocial stress 45
Platelet-derived growth factor (PDGF)
plasma activity, hypertension 9
Pleural effusions
and central hypothyroidism 429
Polyautoimmune syndrome
in common variable immunodeficiency 525
Polycythaemia rubra vera
haematocrit 599
Polymyositis
paraneoplastic, with renal carcinoma 521
Porphyric neuropathy
progression halted by haeme-arginate 611
Postmenopausal women
hypercholesterolaemia, oestradiol effects 453
increase in vertebral BMC 143
Pravastatin
primary hypercholesterolaemia, treatment efficacy 77
Promethazine
increase in vertebral BMC, postmenopausal women 143
Protein kinase C
and insulin resistance 397
Protein-losing gastroenteropathy
in lymphocytic gastritis 95
Prothrombin
and coagulation in CHD, warfarin therapy 303
Psychosocial stress
and cardiovascular risk factors 45
Pulmonary function
chronic obstructive sleep apnoea syndrome 245
COPD 31
Purpura
and cryofibrinogenaemia, skin necrosis 331

Renal artery stenosis
U-NAG levels 281
Renal carcinoma
with paraneoplastic polymyositis 521
Renal failure *see* Chronic renal failure
Renovascular surgery
U-NAG levels before/after surgery 281
Retinal vascular disease
in congenital plasminogen deficiency 619
Rheumatic disease
glucocorticoid-induced osteoporosis 237
Romano–Ward syndrome
in IDDM 227

Scleroderma
and skin hypo/hyperpigmentation 335
Simvastatin
primary hypercholesterolaemia, treatment efficacy 77
Skeletal muscle
denervation and insulin resistance 397
iron deficiency anaemia 149
Skin hypo/hyperpigmentation
in systemic sclerosis 335
Skin necrosis
purpura and cryofibrinogenaemia 331
Sleep complaints, elderly people
chronic obstructive pulmonary disease 31
obstructive sleep apnoea syndrome in obese men 245
Smoking *see* Cigarette smoking
Smooth muscle cells
arteriolar changes in essential hypertension, drug effects 271
growth factor activity and hypertension 9
proliferation in hypertension 9
Social class
risk factor for CVD 309
Staphylococcus aureus
clinical index to predict bacteraemia 83
Streptokinase
platelet aggregation, in AMI/ 513
Stress, psychosocial
and cardiovascular risk factors 45
Sumatriptan
early-morning migraine attacks 211
Syndrome X 25
Systemic sclerosis
scleroderma and 335

Tendon xanthomas
familial hypercholesterolaemia 401
Thrombocytopenia
drug-induced 91
Thromboembolism
in dilated cardiomyopathy 139
Thrombosis
in congenital plasminogen deficiency 619
see also Deep vein thrombosis
Tocopherol, concentrations
risk factor for CHD 53
tPA
and platelet aggregation 513
Transitional cell carcinoma
paraneoplastic leukaemoid reaction 417
Triglycerides
abnormalities in hypertriglyceridaemic patients 217
incidence and mortality in myocardial infarction 17

U-NAG levels
in essential hypertension 281
renal artery stenosis 281
Ultrasonography
Achilles tendon xanthomas 401

Varioliform gastritis
hypoproteinaemia 95
Vena cava, inferior
complete membranous obstruction 501
Venous pressure
follow-up of DVT 71
see also Deep vein thrombosis
Vitamin D
age, sex, season and diet effects 195

Warfarin
decrease of coagulability in CHD 303
inducing haemorrhagic bullae 615
Weight loss
and obstructive sleep apnoea syndrome 245

Xanthomas
familial hypercholesterolaemia 401